Your browser doesn't support javascript.
loading
Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells.
Fan, Yangwei; Ma, Ke; Jing, Jiayu; Wang, Chuying; Hu, Yuan; Shi, Yu; Li, Enxiao; Geng, Qianqian.
Afiliação
  • Fan Y; Department of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an710061, China.
  • Ma K; Department of Medical Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou450052, China.
  • Jing J; Department of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an710061, China.
  • Wang C; Department of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an710061, China.
  • Hu Y; Department of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an710061, China.
  • Shi Y; Department of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an710061, China.
  • Li E; Department of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an710061, China.
  • Geng Q; Department of Nuclear Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an710061, China.
J Cancer ; 11(1): 25-40, 2020.
Article em En | MEDLINE | ID: mdl-31892970
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article